BiotechTubeBiotechTube
Home/Beam Therapeutics/Terrence C. Mulligan
TC

Terrence C. Mulligan

Chief Financial Officer

Beam Therapeutics

Therapeutic Areas

HematologyOncologyGenetic DisordersMetabolic DiseasesLiver Diseases

Beam Therapeutics Pipeline

DrugIndicationPhase
BEAM-101Sickle Cell Disease / Beta-ThalassemiaPhase 1/2
BEAM-201Relapsed/Refractory T-ALL/T-LLPhase 1/2
BEAM-301Glycogen Storage Disease 1a (GSD1a)Preclinical
BEAM-302Alpha-1 Antitrypsin Deficiency (AATD)Preclinical
Undisclosed CAR-T programsHematologic malignanciesDiscovery/Preclinical
Liver-directed programsVarious genetic liver disordersDiscovery/Preclinical
CNS-directed programsNeurological disordersDiscovery/Preclinical

Leadership Team at Beam Therapeutics

JE
John Evans
Chief Executive Officer
GC
Giuseppe Ciaramella
President and Chief Scientific Officer
AG
Anthony G. Quinn
Chief Medical Officer
CW
Christopher Wright
Chief Legal Officer and Corporate Secretary
SK
Susan K. Cole
Chief Business Officer
NV
Nicki Vasquez
Chief Technology Officer, Process & Analytical Development
KW
Katherine Walsh
Chief People Officer
RN
Robert Nelsen
Board Member, Co-founder and Managing Director of ARCH Venture Partners
KB
Kevin Bitterman
Board Member, Partner at Atlas Venture
CP
Cary Pfeffer
Board Member, Operating Partner at Third Rock Ventures
View full Beam Therapeutics profile